Business & funding Story
Anthropic buys Mithril Medicine, a one-person biotech that used an AI assistant, testing a drug-discovery model
Anthropic has acquired Mithril Medicine, a Cambridge, Massachusetts biotech whose only full-time employee was Cody Tranbarger, and says Claude helped take a candidate from idea to promising mouse results in under 18 months.
This story was written with the help of artificial intelligence, checked automatically, then reviewed by an editor before publication, under our AI policy.
What Anthropic bought
Anthropic has acquired Mithril Medicine, a biotechnology company of one person that was developing treatments for two rare forms of muscular dystrophy, according to Anthropic's research post.
Nature, which reported the deal, adds detail on the company's size and assets. Mithril is based in Cambridge, Massachusetts, and its only full-time employee was Cody Tranbarger. According to Nature, it had an AI assistant and two early-stage antibody candidates aimed at a rare form of muscular dystrophy (Nature).
The two accounts differ slightly in wording: Anthropic refers to two forms of the disease, while Nature describes the antibody candidates as targeting one rare form. Neither source, as provided, gives a purchase price.
What Anthropic claims about Claude's role
These points are Anthropic's own claims, not independently verified findings.
- Claude helped Mithril's founder organise contracts, logistics and experiments with 11 external laboratories.
- It helped move a candidate treatment from idea to promising results in mice in under 18 months.
- Anthropic estimates a drug from Mithril could be ready for human clinical trials as early as late 2028, if the candidates continue to hold up.
The timeline is conditional by Anthropic's own wording. The company also states that the work is at an early stage and mostly preclinical, and that it plans to extend Claude's role to clinical trials.
The wider partnerships
Anthropic says it has built deep research partnerships with six organisations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. It reports the following results, all attributed to the company's own announcement:
- Generate Biomedicines: a design proposed with Claude Code was about 70% shorter than the standard version and, in laboratory tests, let immune cells produce about 10 times more receptors.
- Enveda: Claude flagged all 11 issues found by human reviewers across 1,061 pages of documentation, plus seven that they had missed, and human review was reduced by 89%.
- Divergence Labs: Claude generated about 35,000 antibody designs in one month, and the partner found hits for both targeted arms.
The post as summarised does not say how these results compare with conventional methods beyond the figures above.
What Nature reports, and the open questions
Nature's account tempers the one-person framing. Mithril used part-time consultants and at least five contract research organisations, and developing the molecules involved many scientists (Nature).
Tranbarger, now at Anthropic, wrote on LinkedIn that the structure had become a new operating model he calls "Pipeline-in-a-Person". Neither he nor Anthropic agreed to answer Nature's questions.
Researchers quoted by Nature expect more small, AI-backed teams. James Zou of Stanford is among those who hold that view. Jeb Keiper of Third Rock Ventures offers a counterpoint: "it takes a village to develop a drug".
Several matters remain open in the material available: the deal's financial terms, how much of the progress is attributable to Claude rather than to the external labs and consultants, and whether the mouse results will translate to human trials.
| Partner | Reported result |
|---|---|
| Generate Biomedicines | Design about 70% shorter; about 10 times more receptors produced in lab tests |
| Enveda | All 11 human-found issues flagged, plus 7 missed; human review cut by 89%, across 1,061 pages |
| Divergence Labs | About 35,000 antibody designs in one month; hits for both targeted arms |
FAQ
Who was Mithril Medicine's only employee?
According to Nature, the sole full-time employee was Cody Tranbarger, who is now at Anthropic.
When could a Mithril drug reach human trials?
Anthropic estimates as early as late 2028, if the candidates continue to show promise.
Is Mithril's work really the output of one person?
Nature reports that Mithril also used part-time consultants, at least five contract research organisations and many scientists in developing its molecules.
Sources
- https://www.anthropic.com/research/early-progress-drug-development, anthropic.com, (primary source)
- Anthropic bought a one-person, AI-powered biotech: is this drug discovery’s future?, Nature,